|Videos|October 14, 2021
Future Strategies With Lung Cancer Screening
M. Patricia Rivera, MD, a professor of medicine at The University of North Carolina at Chapel Hill, reviews the United States Preventive Services Task Force's lung cancer screening recommendations as of 2021, including the impacted patient populations and effect the recommendations have on direct physician care.
Advertisement
Episodes in this series
M. Patricia Rivera, MD, a professor of medicine at The University of North Carolina at Chapel Hill, reviews the United States Preventive Services Task Force's lung cancer screening recommendations as of 2021, including the impacted patient populations and effect the recommendations have on direct physician care.
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss HER2-mutant NSCLC testing, treatment selection, and sequencing strategies.
The FDA approved sevabertinib for advanced or metastatic nonsquamous NSCLC harboring HER2 (ERBB2) TKD activating mutations.
Durvalumab plus tarlatamab significantly improved OS and PFS vs durvalumab alone as maintenance in extensive-stage SCLC, per topline phase 3 data.
D. Ross Camidge, MD, PhD, and Eric K. Singhi, MD, preview the SCLC and NSCLC abstracts they are anticipating at the 2026 World Conference on Lung Cancer.
The FDA approved camizestrant for ESR1-mutated breast cancer, cleared ropeginterferon alfa-2b for essential thrombocythemia, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Daraxonrasib produced a 42% overall response rate and 16.0-month median OS in previously treated RAS-mutant NSCLC in a phase 1/2 trial.
Advertisement
Advertisement
Trending on OncLive
1
Ofirnoflast Elicits Durable Transfusion Independence, Hematologic Improvement in Lower-Risk MDS
2
Revumenib Plus Chemo Yields High Response and MRD-Negativity Rates in Newly Diagnosed NPM1+ or KMT2A+ AML
3
ACTIVE Regimen Elicits High Response Rates in R/R NPM1-Mutated AML
4
Dr Gangat on Phase 2 Efficacy and Safety Data for DISC-3405 in Polycythemia Vera
5